View DividendFaes Farma マネジメントマネジメント 基準チェック /24現在、CEO に関する十分な情報がありません。主要情報Eduardo de la Cuadra最高経営責任者€1.5m報酬総額CEO給与比率44.25%CEO在任期間2.6yrsCEOの所有権0.01%経営陣の平均在職期間データなし取締役会の平均在任期間7.7yrs経営陣の近況お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., SpainBoard Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Executive Director Eduardo de la Cuadra was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., SpainBoard Change • Feb 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.すべての更新を表示Recent updatesReported Earnings • 12hSecond quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: €191.4m (up 24% from 2Q 2025). Net income: €26.1m (up 8.9% from 2Q 2025). Profit margin: 14% (down from 16% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Spain.新しいナラティブ • Jul 31Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future ProfileCatalysts About Faes Farma Faes Farma is a pharmaceutical and animal nutrition group with a growing international footprint, including Iberia, Latin America and ophthalmology operations through SIFI and Edol. What are the underlying business or industry changes driving this perspective?お知らせ • Jul 08Faes Farma, S.A. to Report First Half, 2026 Results on Jul 30, 2026Faes Farma, S.A. announced that they will report first half, 2026 results on Jul 30, 2026Declared Dividend • Jun 29Dividend of €0.07 announcedShareholders will receive a dividend of €0.07. Ex-date: 2nd July 2026 Payment date: 6th July 2026 Dividend yield will be 2.2%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (101% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 20% over the next 3 years. However, it would need to fall by 41% to increase the payout ratio to a potentially unsustainable range.Major Estimate Revision • Jun 02Consensus EPS estimates increase by 342%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from €0.275 to €1.22. Revenue forecast unchanged at €727.0m. Net income forecast to grow 14% next year vs 135% growth forecast for Pharmaceuticals industry in Spain. Consensus price target of €5.39 unchanged from last update. Share price fell 3.8% to €4.53 over the past week.Declared Dividend • May 11Dividend of €0.07 announcedShareholders will receive a dividend of €0.07. Ex-date: 23rd June 2026 Payment date: 25th June 2026 Dividend yield will be 2.2%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (101% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.New Risk • May 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Profit margins are more than 30% lower than last year (12% net profit margin).お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., SpainReported Earnings • May 05First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.099. Revenue: €200.1m (up 31% from 1Q 2025). Net income: €30.8m (up 8.5% from 1Q 2025). Profit margin: 15% (down from 19% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Pharmaceuticals industry in Spain. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.お知らせ • Apr 10Faes Farma, S.A. to Report Q1, 2026 Results on Apr 30, 2026Faes Farma, S.A. announced that they will report Q1, 2026 results on Apr 30, 2026New Risk • Mar 13New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 22% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (13% net profit margin).Price Target Changed • Feb 23Price target increased by 8.7% to €5.30Up from €4.88, the current price target is an average from 4 analysts. New target price is 6.4% above last closing price of €4.98. Stock is up 34% over the past year. The company is forecast to post earnings per share of €0.23 for next year compared to €0.36 last year.お知らせ • Feb 03Faes Farma, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Faes Farma, S.A. announced that they will report fiscal year 2025 results on Feb 26, 2026Upcoming Dividend • Jan 02Upcoming dividend of €0.033 per shareEligible shareholders must have bought the stock before 08 January 2026. Payment date: 12 January 2026. Trailing yield: 3.0%. Lower than top quartile of Spanish dividend payers (5.3%). Higher than average of industry peers (2.6%).Declared Dividend • Nov 24Dividend of €0.033 announcedShareholders will receive a dividend of €0.033. Ex-date: 8th January 2026 Payment date: 12th January 2026 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.Reported Earnings • Nov 06Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: €0.068. Revenue: €146.6m (up 23% from 3Q 2024). Net income: €21.2m (down 1.2% from 3Q 2024). Profit margin: 14% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Spain.お知らせ • Nov 06Faes Farma, S.A. to Report Nine Months, 2025 Results on Nov 04, 2025Faes Farma, S.A. announced that they will report nine months, 2025 results on Nov 04, 2025Major Estimate Revision • Oct 16Consensus EPS estimates fall by 22%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €538.5m to €557.0m. EPS estimate fell from €0.27 to €0.21 per share. Net income forecast to shrink 24% next year vs 24% growth forecast for Pharmaceuticals industry in Spain . Consensus price target up from €4.88 to €5.18. Share price rose 2.7% to €4.50 over the past week.Reported Earnings • Jul 25Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €154.4m (up 15% from 2Q 2024). Net income: €24.0m (down 14% from 2Q 2024). Profit margin: 16% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.お知らせ • Jul 22Faes Farma, S.A. to Report First Half, 2025 Results on Jul 24, 2025Faes Farma, S.A. announced that they will report first half, 2025 results on Jul 24, 2025Buy Or Sell Opportunity • Jul 15Now 21% undervaluedOver the last 90 days, the stock has risen 18% to €4.53. The fair value is estimated to be €5.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 7.4%. Revenue is forecast to grow by 6.8% in 2 years. Earnings are forecast to decline by 5.3% in the next 2 years.Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Executive Director Eduardo de la Cuadra was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.分析記事 • Jun 12Here's Why We Think Faes Farma (BME:FAE) Might Deserve Your Attention TodayIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Price Target Changed • Jun 11Price target increased by 12% to €4.78Up from €4.28, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.56. Stock is up 21% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.お知らせ • Jun 11Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million.Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million on June 10, 2025. Faes Farma, S.A. will pay an earnout/contingent payment of €80.5 million cash. The transaction values Sifi S.P.A. at €270 million upfront Enterprise Value plus earn outs related to Akantior linked to certain sales levels in Europe that exceed forecasts. The maximum total amount of the earn-outs would be €50.5 million spread over six milestones/payments until 2041. In addition, there is a potential payment of €30 million conditional on the commercial launch of Akantior in the US plus one digit to low two-digit tiered payments on US net sales following until the expiration of the patent in the US, or US loss of exclusivity. Sifi S.P.A. acquisition expected to be EPS accretive from year one, even before commercial and cost synergies. Faes Farma, S.A. has secured committed debt financing from J.P. Morgan SE to fund the acquisition. The transaction is expected to close in the third quarter of 2025, subject to approval by competition and foreign investment authorities in the various countries and Faes Farma, S.A.'s extraordinary shareholders' meeting, which will be convened in the coming days. J.P. Morgan SE acted as financial advisor for Faes Farma, S.A. Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor for Faes Farma, S.A. Chiomenti Studio Legale acted as legal advisor for Faes Farma, S.A. Ernst & Young Transaction Advisory Services España acted as due diligence provider for Faes Farma, S.A. Gide Loyrette Nouel A.A.R.P.I. acted as due diligence provider for Faes Farma, S.A. Wolf Theiss Rechtsanwalte GmbH & Co Kg acted as due diligence provider for Faes Farma, S.A. At Kearney Sa acted as due diligence provider for Faes Farma, S.A. Evercore Partners International LLP acted as financial advisor for 21 Invest Sgr S.p.A. Mediobanca Banca di Credito Finanziario S.p.A. acted as financial advisor for 21 Invest Sgr S.p.A. Hogan Lovells Studio Legale acted as legal advisor for 21 Invest Sgr S.p.A.お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., SpainNew Risk • May 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.3% average weekly change). Large one-off items impacting financial results.Reported Earnings • May 07First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.091. Revenue: €153.0m (up 10% from 1Q 2024). Net income: €28.4m (down 6.9% from 1Q 2024). Profit margin: 19% (down from 22% in 1Q 2024). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Spain.Price Target Changed • May 06Price target increased by 12% to €4.51Up from €4.03, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.31. Stock is up 23% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.Major Estimate Revision • Apr 24Consensus EPS estimates fall by 15%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €515.5m to €524.8m. EPS estimate fell from €0.305 to €0.26 per share. Net income forecast to shrink 25% next year vs 21% growth forecast for Pharmaceuticals industry in Spain . Consensus price target up from €4.03 to €4.28. Share price rose 5.4% to €4.09 over the past week.Price Target Changed • Apr 23Price target increased by 13% to €4.28Up from €3.78, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.12. Stock is up 26% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.分析記事 • Apr 11Improved Earnings Required Before Faes Farma, S.A. (BME:FAE) Shares Find Their FeetWhen close to half the companies in Spain have price-to-earnings ratios (or "P/E's") above 18x, you may consider Faes...お知らせ • Apr 09Faes Farma, S.A. to Report Q1, 2025 Results on Apr 30, 2025Faes Farma, S.A. announced that they will report Q1, 2025 results on Apr 30, 2025Price Target Changed • Mar 26Price target increased by 7.3% to €4.03Up from €3.75, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €3.90. Stock is up 24% over the past year.お知らせ • Mar 26Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A.Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A. on March 25, 2025. Laboratorios Edol Productos Farmacêuticos has reported sales of exceeding €30 million in 2024. The closing of the transaction is subject to the satisfactory completion of conditions precedent, including the submission of audited annual accounts for 2024 and the continuation of some of the existing commercial agreements with Laboratorios Edol.分析記事 • Mar 01Does Faes Farma (BME:FAE) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...お知らせ • Feb 13Faes Farma, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Faes Farma, S.A. announced that they will report fiscal year 2024 results at 12:00 PM, Romance Standard Time on Feb 28, 2025Board Change • Feb 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Jan 06Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332Faes Farma, S.A. ( BME:FAE ) will pay a dividend of €0.0332 on the 13th of January. This makes the dividend yield 4.5...Upcoming Dividend • Jan 02Upcoming dividend of €0.033 per shareEligible shareholders must have bought the stock before 09 January 2025. Payment date: 13 January 2025. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 4.5%. Lower than top quartile of Spanish dividend payers (5.6%). Higher than average of industry peers (2.7%).分析記事 • Dec 03Faes Farma's (BME:FAE) Dividend Will Be €0.0332The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend on the 13th of January, with...Declared Dividend • Dec 02Dividend of €0.033 announcedShareholders will receive a dividend of €0.033. Ex-date: 9th January 2025 Payment date: 13th January 2025 Dividend yield will be 3.6%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (109% cash payout ratio). The dividend has increased by an average of 7.6% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to decline by 4.5% over the next 3 years. However, it would need to fall by 59% to increase the payout ratio to a potentially unsustainable range.Buy Or Sell Opportunity • Nov 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.5% to €3.47. The fair value is estimated to be €4.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 3.1%. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings are forecast to decline by 2.8% per annum over the same time period.分析記事 • Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesAs you might know, Faes Farma, S.A. ( BME:FAE ) recently reported its third-quarter numbers. It was an okay result...Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.069. Revenue: €119.3m (up 9.4% from 3Q 2023). Net income: €21.5m (up 1.5% from 3Q 2023). Profit margin: 18% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.Reported Earnings • Aug 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €134.6m (up 9.5% from 2Q 2023). Net income: €27.9m (up 9.9% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe.Buy Or Sell Opportunity • May 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €3.49. The fair value is estimated to be €2.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Earnings per share has grown by 4.2%. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are forecast to decline by 1.9% per annum over the same time period.分析記事 • Mar 01Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts ThinkFaes Farma, S.A. ( BME:FAE ) came out with its annual results last week, and we wanted to see how the business is...Reported Earnings • Feb 29Full year 2023 earnings releasedFull year 2023 results: Revenue: €473.1m (up 2.5% from FY 2022). Net income: €91.9m (up 2.6% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Spain.お知らせ • Feb 09Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024Faes Farma, S.A. announced that they will report fiscal year 2023 results on Feb 27, 2024お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.Buy Or Sell Opportunity • Jan 29Now 21% undervaluedOver the last 90 days, the stock has risen 2.0% to €3.03. The fair value is estimated to be €3.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 4.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are forecast to decline by 0.8% per annum over the same time period.New Risk • Jan 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).分析記事 • Dec 18Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend of €0.0316 per share on the 15th of...分析記事 • Dec 04Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend of €0.0316 per share on the 15th of...分析記事 • Nov 24Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Oct 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).New Risk • Jul 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €122.9m (up 1.7% from 2Q 2022). Net income: €25.4m (down 3.4% from 2Q 2022). Profit margin: 21% (down from 22% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.お知らせ • May 05Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci.Faes Farma, S.A. (BME:FAE) agreed to acquire NovoSci on January 12, 2023. Faes Farma received authorization for the acquisition. Mariano Ucar, Ariadna Casanueva and Soraya Romero of Cuatrecasas acted as legal advisors to Faes Farma in the transaction.Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci on May 3, 2023.Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €130.1m (up 4.0% from 1Q 2022). Net income: €27.6m (up 3.7% from 1Q 2022). Profit margin: 21% (in line with 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.分析記事 • May 03Here's Why Faes Farma (BME:FAE) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Buying Opportunity • Mar 01Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 7.5%. The fair value is estimated to be €4.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 7.0%. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings is also forecast to grow by 2.5% per annum over the same time period.Upcoming Dividend • Dec 29Upcoming dividend of €0.03 per shareEligible shareholders must have bought the stock before 05 January 2023. Payment date: 09 January 2023. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 5.8%. Lower than top quartile of Spanish dividend payers (6.0%). Higher than average of industry peers (2.6%).Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Nov 04Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €106.0m (down 5.2% from 3Q 2021). Net income: €21.1m (down 11% from 3Q 2021). Profit margin: 20% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.分析記事 • Sep 21Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?Does the September share price for Faes Farma, S.A. ( BME:FAE ) reflect what it's really worth? Today, we will estimate...分析記事 • Aug 03Is Faes Farma (BME:FAE) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €120.9m (up 16% from 2Q 2021). Net income: €26.3m (up 2.3% from 2Q 2021). Profit margin: 22% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 4.9% compared to a 4.3% growth forecast for the industry in Spain.分析記事 • Jun 17Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings GrowthIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.分析記事 • Mar 27Is Faes Farma (BME:FAE) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: EPS: €0.29 (up from €0.26 in FY 2020). Revenue: €428.6m (up 4.2% from FY 2020). Net income: €83.2m (up 15% from FY 2020). Profit margin: 19% (up from 18% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Over the next year, revenue is expected to shrink by 1.4% compared to a 7.3% growth forecast for the pharmaceuticals industry in Spain. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.分析記事 • Dec 13Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will be increasing its dividend on the 23rd of December...Upcoming Dividend • Dec 09Upcoming dividend of €0.14 per shareEligible shareholders must have bought the stock before 16 December 2021. Payment date: 23 December 2021. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Spanish dividend payers (5.3%). Higher than average of industry peers (2.6%).分析記事 • Nov 29Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17Faes Farma, S.A. ( BME:FAE ) will increase its dividend on the 23rd of December to €0.17. This takes the dividend yield...分析記事 • Sep 21Is Faes Farma (BME:FAE) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...分析記事 • Jul 31Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This YearLast week saw the newest half-yearly earnings release from Faes Farma, S.A. ( BME:FAE ), an important milestone in the...Reported Earnings • Jul 29Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €104.1m (up 4.4% from 2Q 2020). Net income: €25.7m (up 3.9% from 2Q 2020). Profit margin: 25% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Reported Earnings • May 04First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €104.9m (down 14% from 1Q 2020). Net income: €21.5m (up 3.1% from 1Q 2020). Profit margin: 21% (up from 17% in 1Q 2020). The increase in margin was driven by lower expenses.分析記事 • May 01Is Faes Farma (BME:FAE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...分析記事 • Apr 07Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)Does the April share price for Faes Farma, S.A. ( BME:FAE ) reflect what it's really worth? Today, we will estimate the...分析記事 • Mar 22Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?Today we'll take a closer look at Faes Farma, S.A. ( BME:FAE ) from a dividend investor's perspective. Owning a strong...分析記事 • Mar 06Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak FoundationsFaes Farma, S.A.'s ( BME:FAE ) healthy profit numbers didn't contain any surprises for investors. We think this is due...分析記事 • Feb 22Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their InvestmentWhen we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...Is New 90 Day High Low • Jan 18New 90-day high: €3.96The company is up 22% from its price of €3.26 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.14 per share.分析記事 • Jan 16I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With EaseSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...分析記事 • Dec 08Faes Farma (BME:FAE) Seems To Use Debt Rather SparinglyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Dec 04New 90-day high: €3.90The company is up 19% from its price of €3.27 on 04 September 2020. The Spanish market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.Is New 90 Day High Low • Nov 16New 90-day high: €3.74The company is up 9.0% from its price of €3.44 on 18 August 2020. The Spanish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.Is New 90 Day High Low • Oct 29New 90-day low: €3.20The company is down 12% from its price of €3.63 on 30 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.CEO報酬分析Faes Farma の収益と比較して、Eduardo de la Cuadra の報酬はどのように変化したか？日付総報酬給与会社業績Jun 30 2026n/an/a€84mMar 31 2026n/an/a€82mDec 31 2025€1m€650k€80mSep 30 2025n/an/a€105mJun 30 2025n/an/a€105mMar 31 2025n/an/a€109mDec 31 2024€522k€217k€111m報酬と市場: Eduardoの 総報酬 ($USD 1.69M ) は、 Spanish市場 ($USD 1.51M ) の同様の規模の企業の平均とほぼ同じです。報酬と収益: Eduardoの報酬は 20% 以上増加しましたが、会社の収益は過去 1 年間で 20% 以上減少しました。CEOEduardo de la Cuadra 2.6yrs在職期間€1,469,000報酬Mr. Eduardo Recoder de la Cuadra is Executive Director of Faes Farma, S.A. from June 25, 2024 and has been its Chief Executive Officer.取締役名称ポジション在職期間報酬所有権Eduardo de la CuadraCEO & Executive Director2.2yrs€1.47m0.010% € 142.3kBelen CorbiIndependent Director8.2yrs€128.00kデータなしGonzalo Fernández de Valderrama IribarnegarayDirector23.2yrs€100.00k0.48% € 6.7mIñigo Zavala de la TorreDirector32.2yrs€100.00k0.83% € 11.7mMariano Ucar AnguloNon-Executive Chairman of the Board of Directors35.3yrs€2.11m0.40% € 5.5mCarmen Basagoiti PastorDirector15.1yrs€100.00k0.010% € 142.3kNuria LapeñaIndependent Director4.2yrs€115.00kデータなしMaria Zugaza SalazarIndependent Director7.2yrs€128.00kデータなしEnrique PlazaIndependent Director4.2yrs€114.00k0.010% € 142.3kBeatriz Faro MoralesIndependent Director1.2yrs€47.00kデータなしもっと見る7.7yrs平均在職期間経験豊富なボード: FAEの 取締役会 は 経験豊富 であると考えられます ( 7.7年の平均在任期間)。View Ownership企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/04 13:51終値2026/08/03 00:00収益2026/06/30年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Faes Farma, S.A. 4 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9 アナリスト機関Javier Esteban LarioBanco de Sabadell. S.A.Jesús Gómez DominguezBanco SantanderJosé Romero HerreroBanco Santander6 その他のアナリストを表示
お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., Spain
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Executive Director Eduardo de la Cuadra was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., Spain
Board Change • Feb 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • 12hSecond quarter 2026 earnings releasedSecond quarter 2026 results: Revenue: €191.4m (up 24% from 2Q 2025). Net income: €26.1m (up 8.9% from 2Q 2025). Profit margin: 14% (down from 16% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.3% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Spain.
新しいナラティブ • Jul 31Latin American Expansion And Ophthalmology Integration Will Reshape This Pharma Group’s Future ProfileCatalysts About Faes Farma Faes Farma is a pharmaceutical and animal nutrition group with a growing international footprint, including Iberia, Latin America and ophthalmology operations through SIFI and Edol. What are the underlying business or industry changes driving this perspective?
お知らせ • Jul 08Faes Farma, S.A. to Report First Half, 2026 Results on Jul 30, 2026Faes Farma, S.A. announced that they will report first half, 2026 results on Jul 30, 2026
Declared Dividend • Jun 29Dividend of €0.07 announcedShareholders will receive a dividend of €0.07. Ex-date: 2nd July 2026 Payment date: 6th July 2026 Dividend yield will be 2.2%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (101% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to decline by 20% over the next 3 years. However, it would need to fall by 41% to increase the payout ratio to a potentially unsustainable range.
Major Estimate Revision • Jun 02Consensus EPS estimates increase by 342%The consensus outlook for fiscal year 2026 has been updated. 2026 EPS estimate increased from €0.275 to €1.22. Revenue forecast unchanged at €727.0m. Net income forecast to grow 14% next year vs 135% growth forecast for Pharmaceuticals industry in Spain. Consensus price target of €5.39 unchanged from last update. Share price fell 3.8% to €4.53 over the past week.
Declared Dividend • May 11Dividend of €0.07 announcedShareholders will receive a dividend of €0.07. Ex-date: 23rd June 2026 Payment date: 25th June 2026 Dividend yield will be 2.2%, which is lower than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (53% earnings payout ratio) but not covered by cash flows (101% cash payout ratio). The dividend has increased by an average of 8.4% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 54% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
New Risk • May 07New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 18% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (18% operating cash flow to total debt). Minor Risks Dividend is not well covered by cash flows (101% cash payout ratio). Profit margins are more than 30% lower than last year (12% net profit margin).
お知らせ • May 07Faes Farma, S.A., Annual General Meeting, Jun 24, 2026Faes Farma, S.A., Annual General Meeting, Jun 24, 2026. Location: palacio euskalduna, avenida abandoibarra 4, bilbao., Spain
Reported Earnings • May 05First quarter 2026 earnings releasedFirst quarter 2026 results: EPS: €0.099. Revenue: €200.1m (up 31% from 1Q 2025). Net income: €30.8m (up 8.5% from 1Q 2025). Profit margin: 15% (down from 19% in 1Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.9% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Pharmaceuticals industry in Spain. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
お知らせ • Apr 10Faes Farma, S.A. to Report Q1, 2026 Results on Apr 30, 2026Faes Farma, S.A. announced that they will report Q1, 2026 results on Apr 30, 2026
New Risk • Mar 13New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 13% Last year net profit margin: 22% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Profit margins are more than 30% lower than last year (13% net profit margin).
Price Target Changed • Feb 23Price target increased by 8.7% to €5.30Up from €4.88, the current price target is an average from 4 analysts. New target price is 6.4% above last closing price of €4.98. Stock is up 34% over the past year. The company is forecast to post earnings per share of €0.23 for next year compared to €0.36 last year.
お知らせ • Feb 03Faes Farma, S.A. to Report Fiscal Year 2025 Results on Feb 26, 2026Faes Farma, S.A. announced that they will report fiscal year 2025 results on Feb 26, 2026
Upcoming Dividend • Jan 02Upcoming dividend of €0.033 per shareEligible shareholders must have bought the stock before 08 January 2026. Payment date: 12 January 2026. Trailing yield: 3.0%. Lower than top quartile of Spanish dividend payers (5.3%). Higher than average of industry peers (2.6%).
Declared Dividend • Nov 24Dividend of €0.033 announcedShareholders will receive a dividend of €0.033. Ex-date: 8th January 2026 Payment date: 12th January 2026 Dividend yield will be 3.1%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by both earnings (50% earnings payout ratio) and cash flows (67% cash payout ratio). The dividend has increased by an average of 7.0% per year over the past 10 years. However, payments have been volatile during that time. EPS is expected to grow by 25% over the next 3 years, which should provide support to the dividend and adequate earnings cover.
Reported Earnings • Nov 06Third quarter 2025 earnings releasedThird quarter 2025 results: EPS: €0.068. Revenue: €146.6m (up 23% from 3Q 2024). Net income: €21.2m (down 1.2% from 3Q 2024). Profit margin: 14% (down from 18% in 3Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 8.2% p.a. on average during the next 3 years, compared to a 8.8% growth forecast for the Pharmaceuticals industry in Spain.
お知らせ • Nov 06Faes Farma, S.A. to Report Nine Months, 2025 Results on Nov 04, 2025Faes Farma, S.A. announced that they will report nine months, 2025 results on Nov 04, 2025
Major Estimate Revision • Oct 16Consensus EPS estimates fall by 22%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €538.5m to €557.0m. EPS estimate fell from €0.27 to €0.21 per share. Net income forecast to shrink 24% next year vs 24% growth forecast for Pharmaceuticals industry in Spain . Consensus price target up from €4.88 to €5.18. Share price rose 2.7% to €4.50 over the past week.
Reported Earnings • Jul 25Second quarter 2025 earnings releasedSecond quarter 2025 results: Revenue: €154.4m (up 15% from 2Q 2024). Net income: €24.0m (down 14% from 2Q 2024). Profit margin: 16% (down from 21% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 7.5% p.a. on average during the next 3 years, compared to a 5.7% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 7% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth.
お知らせ • Jul 22Faes Farma, S.A. to Report First Half, 2025 Results on Jul 24, 2025Faes Farma, S.A. announced that they will report first half, 2025 results on Jul 24, 2025
Buy Or Sell Opportunity • Jul 15Now 21% undervaluedOver the last 90 days, the stock has risen 18% to €4.53. The fair value is estimated to be €5.74, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.5% over the last 3 years. Earnings per share has grown by 7.4%. Revenue is forecast to grow by 6.8% in 2 years. Earnings are forecast to decline by 5.3% in the next 2 years.
Board Change • Jul 01Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 4 experienced directors. 5 highly experienced directors. Executive Director Eduardo de la Cuadra was the last director to join the board, commencing their role in 2024. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
分析記事 • Jun 12Here's Why We Think Faes Farma (BME:FAE) Might Deserve Your Attention TodayIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Price Target Changed • Jun 11Price target increased by 12% to €4.78Up from €4.28, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.56. Stock is up 21% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.
お知らせ • Jun 11Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million.Faes Farma, S.A. (BME:FAE) has signed a purchase agreement to acquire Sifi S.P.A. from 21 Investimenti III Fund managed by 21 Invest Sgr S.p.A. and others for €350 million on June 10, 2025. Faes Farma, S.A. will pay an earnout/contingent payment of €80.5 million cash. The transaction values Sifi S.P.A. at €270 million upfront Enterprise Value plus earn outs related to Akantior linked to certain sales levels in Europe that exceed forecasts. The maximum total amount of the earn-outs would be €50.5 million spread over six milestones/payments until 2041. In addition, there is a potential payment of €30 million conditional on the commercial launch of Akantior in the US plus one digit to low two-digit tiered payments on US net sales following until the expiration of the patent in the US, or US loss of exclusivity. Sifi S.P.A. acquisition expected to be EPS accretive from year one, even before commercial and cost synergies. Faes Farma, S.A. has secured committed debt financing from J.P. Morgan SE to fund the acquisition. The transaction is expected to close in the third quarter of 2025, subject to approval by competition and foreign investment authorities in the various countries and Faes Farma, S.A.'s extraordinary shareholders' meeting, which will be convened in the coming days. J.P. Morgan SE acted as financial advisor for Faes Farma, S.A. Cuatrecasas, Gonçalves Pereira, S.L.P. acted as legal advisor for Faes Farma, S.A. Chiomenti Studio Legale acted as legal advisor for Faes Farma, S.A. Ernst & Young Transaction Advisory Services España acted as due diligence provider for Faes Farma, S.A. Gide Loyrette Nouel A.A.R.P.I. acted as due diligence provider for Faes Farma, S.A. Wolf Theiss Rechtsanwalte GmbH & Co Kg acted as due diligence provider for Faes Farma, S.A. At Kearney Sa acted as due diligence provider for Faes Farma, S.A. Evercore Partners International LLP acted as financial advisor for 21 Invest Sgr S.p.A. Mediobanca Banca di Credito Finanziario S.p.A. acted as financial advisor for 21 Invest Sgr S.p.A. Hogan Lovells Studio Legale acted as legal advisor for 21 Invest Sgr S.p.A.
お知らせ • May 20Faes Farma, S.A., Annual General Meeting, Jun 24, 2025Faes Farma, S.A., Annual General Meeting, Jun 24, 2025. Location: palacio euskalduna, avenida abandoibarra, n 4, de bilbao., Spain
New Risk • May 13New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Spanish stocks, typically moving 5.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.3% average weekly change). Large one-off items impacting financial results.
Reported Earnings • May 07First quarter 2025 earnings releasedFirst quarter 2025 results: EPS: €0.091. Revenue: €153.0m (up 10% from 1Q 2024). Net income: €28.4m (down 6.9% from 1Q 2024). Profit margin: 19% (down from 22% in 1Q 2024). Revenue is forecast to grow 6.2% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Pharmaceuticals industry in Spain.
Price Target Changed • May 06Price target increased by 12% to €4.51Up from €4.03, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.31. Stock is up 23% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.
Major Estimate Revision • Apr 24Consensus EPS estimates fall by 15%, revenue upgradedThe consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from €515.5m to €524.8m. EPS estimate fell from €0.305 to €0.26 per share. Net income forecast to shrink 25% next year vs 21% growth forecast for Pharmaceuticals industry in Spain . Consensus price target up from €4.03 to €4.28. Share price rose 5.4% to €4.09 over the past week.
Price Target Changed • Apr 23Price target increased by 13% to €4.28Up from €3.78, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €4.12. Stock is up 26% over the past year. The company is forecast to post earnings per share of €0.26 for next year compared to €0.36 last year.
分析記事 • Apr 11Improved Earnings Required Before Faes Farma, S.A. (BME:FAE) Shares Find Their FeetWhen close to half the companies in Spain have price-to-earnings ratios (or "P/E's") above 18x, you may consider Faes...
お知らせ • Apr 09Faes Farma, S.A. to Report Q1, 2025 Results on Apr 30, 2025Faes Farma, S.A. announced that they will report Q1, 2025 results on Apr 30, 2025
Price Target Changed • Mar 26Price target increased by 7.3% to €4.03Up from €3.75, the current price target is an average from 4 analysts. New target price is approximately in line with last closing price of €3.90. Stock is up 24% over the past year.
お知らせ • Mar 26Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A.Faes Farma, S.A. (BME:FAE) agreed to acquire Laboratorios Edol Productos Farmacêuticos, S.A. on March 25, 2025. Laboratorios Edol Productos Farmacêuticos has reported sales of exceeding €30 million in 2024. The closing of the transaction is subject to the satisfactory completion of conditions precedent, including the submission of audited annual accounts for 2024 and the continuation of some of the existing commercial agreements with Laboratorios Edol.
分析記事 • Mar 01Does Faes Farma (BME:FAE) Deserve A Spot On Your Watchlist?For beginners, it can seem like a good idea (and an exciting prospect) to buy a company that tells a good story to...
お知らせ • Feb 13Faes Farma, S.A. to Report Fiscal Year 2024 Results on Feb 28, 2025Faes Farma, S.A. announced that they will report fiscal year 2024 results at 12:00 PM, Romance Standard Time on Feb 28, 2025
Board Change • Feb 07Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 4 experienced directors. 4 highly experienced directors. 4 independent directors (5 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Jan 06Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0332Faes Farma, S.A. ( BME:FAE ) will pay a dividend of €0.0332 on the 13th of January. This makes the dividend yield 4.5...
Upcoming Dividend • Jan 02Upcoming dividend of €0.033 per shareEligible shareholders must have bought the stock before 09 January 2025. Payment date: 13 January 2025. Payout ratio is a comfortable 50% but the company is paying out more than the cash it is generating. Trailing yield: 4.5%. Lower than top quartile of Spanish dividend payers (5.6%). Higher than average of industry peers (2.7%).
分析記事 • Dec 03Faes Farma's (BME:FAE) Dividend Will Be €0.0332The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend on the 13th of January, with...
Declared Dividend • Dec 02Dividend of €0.033 announcedShareholders will receive a dividend of €0.033. Ex-date: 9th January 2025 Payment date: 13th January 2025 Dividend yield will be 3.6%, which is higher than the industry average of 2.4%. Sustainability & Growth Dividend is covered by earnings (37% earnings payout ratio) but not covered by cash flows (109% cash payout ratio). The dividend has increased by an average of 7.6% per year over the past 9 years. However, payments have been volatile during that time. EPS is expected to decline by 4.5% over the next 3 years. However, it would need to fall by 59% to increase the payout ratio to a potentially unsustainable range.
Buy Or Sell Opportunity • Nov 18Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 4.5% to €3.47. The fair value is estimated to be €4.37, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 4.9% over the last 3 years. Earnings per share has grown by 3.1%. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings are forecast to decline by 2.8% per annum over the same time period.
分析記事 • Nov 03Faes Farma, S.A. (BME:FAE) Just Released Its Third-Quarter Results And Analysts Are Updating Their EstimatesAs you might know, Faes Farma, S.A. ( BME:FAE ) recently reported its third-quarter numbers. It was an okay result...
Reported Earnings • Nov 01Third quarter 2024 earnings releasedThird quarter 2024 results: EPS: €0.069. Revenue: €119.3m (up 9.4% from 3Q 2023). Net income: €21.5m (up 1.5% from 3Q 2023). Profit margin: 18% (down from 19% in 3Q 2023). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 1.0% p.a. on average during the next 3 years, compared to a 7.4% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 3% per year whereas the company’s share price has remained flat.
Reported Earnings • Aug 01Second quarter 2024 earnings releasedSecond quarter 2024 results: Revenue: €134.6m (up 9.5% from 2Q 2023). Net income: €27.9m (up 9.9% from 2Q 2023). Profit margin: 21% (in line with 2Q 2023). Revenue is forecast to grow 1.1% p.a. on average during the next 3 years, compared to a 7.8% growth forecast for the Pharmaceuticals industry in Europe.
Buy Or Sell Opportunity • May 06Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 13% to €3.49. The fair value is estimated to be €2.88, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 6.3% over the last 3 years. Earnings per share has grown by 4.2%. For the next 3 years, revenue is forecast to grow by 1.6% per annum. Earnings are forecast to decline by 1.9% per annum over the same time period.
分析記事 • Mar 01Faes Farma, S.A. (BME:FAE) Just Released Its Full-Year Earnings: Here's What Analysts ThinkFaes Farma, S.A. ( BME:FAE ) came out with its annual results last week, and we wanted to see how the business is...
Reported Earnings • Feb 29Full year 2023 earnings releasedFull year 2023 results: Revenue: €473.1m (up 2.5% from FY 2022). Net income: €91.9m (up 2.6% from FY 2022). Profit margin: 19% (in line with FY 2022). Revenue is forecast to grow 1.6% p.a. on average during the next 3 years, compared to a 5.6% growth forecast for the Pharmaceuticals industry in Spain.
お知らせ • Feb 09Faes Farma, S.A. to Report Fiscal Year 2023 Results on Feb 27, 2024Faes Farma, S.A. announced that they will report fiscal year 2023 results on Feb 27, 2024
お知らせ • Feb 08Faes Farma, S.A., Annual General Meeting, Jun 15, 2024Faes Farma, S.A., Annual General Meeting, Jun 15, 2024.
Buy Or Sell Opportunity • Jan 29Now 21% undervaluedOver the last 90 days, the stock has risen 2.0% to €3.03. The fair value is estimated to be €3.83, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 6.4% over the last 3 years. Earnings per share has grown by 4.3%. For the next 3 years, revenue is forecast to grow by 2.5% per annum. Earnings are forecast to decline by 0.8% per annum over the same time period.
New Risk • Jan 22New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.8% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.8% per year for the foreseeable future. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
分析記事 • Dec 18Faes Farma (BME:FAE) Is Due To Pay A Dividend Of €0.0316The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend of €0.0316 per share on the 15th of...
分析記事 • Dec 04Faes Farma (BME:FAE) Will Pay A Dividend Of €0.0316The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will pay a dividend of €0.0316 per share on the 15th of...
分析記事 • Nov 24Does Faes Farma (BME:FAE) Have A Healthy Balance Sheet?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Oct 25New major risk - Revenue and earnings growthEarnings are forecast to decline by an average of 0.2% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risk Earnings are forecast to decline by an average of 0.2% per year for the foreseeable future. Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
New Risk • Jul 31New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (2.6% increase in shares outstanding).
Reported Earnings • Jul 30Second quarter 2023 earnings releasedSecond quarter 2023 results: Revenue: €122.9m (up 1.7% from 2Q 2022). Net income: €25.4m (down 3.4% from 2Q 2022). Profit margin: 21% (down from 22% in 2Q 2022). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 3.1% p.a. on average during the next 3 years, compared to a 6.1% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 4% per year, which means it is significantly lagging earnings.
お知らせ • May 05Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci.Faes Farma, S.A. (BME:FAE) agreed to acquire NovoSci on January 12, 2023. Faes Farma received authorization for the acquisition. Mariano Ucar, Ariadna Casanueva and Soraya Romero of Cuatrecasas acted as legal advisors to Faes Farma in the transaction.Faes Farma, S.A. (BME:FAE) completed the acquisition of NovoSci on May 3, 2023.
Reported Earnings • May 03First quarter 2023 earnings releasedFirst quarter 2023 results: Revenue: €130.1m (up 4.0% from 1Q 2022). Net income: €27.6m (up 3.7% from 1Q 2022). Profit margin: 21% (in line with 1Q 2022). Revenue is forecast to grow 3.3% p.a. on average during the next 3 years, compared to a 6.2% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
分析記事 • May 03Here's Why Faes Farma (BME:FAE) Can Manage Its Debt ResponsiblySome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Buying Opportunity • Mar 01Now 20% undervalued after recent price dropOver the last 90 days, the stock is down 7.5%. The fair value is estimated to be €4.25, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 5.9% over the last 3 years. Earnings per share has grown by 7.0%. For the next 3 years, revenue is forecast to grow by 1.0% per annum. Earnings is also forecast to grow by 2.5% per annum over the same time period.
Upcoming Dividend • Dec 29Upcoming dividend of €0.03 per shareEligible shareholders must have bought the stock before 05 January 2023. Payment date: 09 January 2023. Payout ratio is on the higher end at 81%, however this is supported by cash flows. Trailing yield: 5.8%. Lower than top quartile of Spanish dividend payers (6.0%). Higher than average of industry peers (2.6%).
Board Change • Nov 16Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Nov 04Third quarter 2022 earnings releasedThird quarter 2022 results: Revenue: €106.0m (down 5.2% from 3Q 2021). Net income: €21.1m (down 11% from 3Q 2021). Profit margin: 20% (down from 21% in 3Q 2021). The decrease in margin was driven by lower revenue. Revenue is forecast to grow 2.5% p.a. on average during the next 3 years, compared to a 5.9% growth forecast for the Pharmaceuticals industry in Europe. Over the last 3 years on average, earnings per share has increased by 10% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
分析記事 • Sep 21Is There An Opportunity With Faes Farma, S.A.'s (BME:FAE) 50% Undervaluation?Does the September share price for Faes Farma, S.A. ( BME:FAE ) reflect what it's really worth? Today, we will estimate...
分析記事 • Aug 03Is Faes Farma (BME:FAE) A Risky Investment?Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Jul 30Second quarter 2022 earnings releasedSecond quarter 2022 results: Revenue: €120.9m (up 16% from 2Q 2021). Net income: €26.3m (up 2.3% from 2Q 2021). Profit margin: 22% (down from 25% in 2Q 2021). The decrease in margin was driven by higher expenses. Over the next year, revenue is expected to shrink by 4.9% compared to a 4.3% growth forecast for the industry in Spain.
分析記事 • Jun 17Faes Farma (BME:FAE) Ticks All The Boxes When It Comes To Earnings GrowthIt's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story...
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was an independent director. The company's board is composed of: 1 new director. 1 experienced director. 5 highly experienced directors. 3 independent directors (4 non-independent directors). Independent Director Eugenia Zugaza Salazar was the last independent director to join the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
分析記事 • Mar 27Is Faes Farma (BME:FAE) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Feb 27Full year 2021 earnings: EPS and revenues exceed analyst expectationsFull year 2021 results: EPS: €0.29 (up from €0.26 in FY 2020). Revenue: €428.6m (up 4.2% from FY 2020). Net income: €83.2m (up 15% from FY 2020). Profit margin: 19% (up from 18% in FY 2020). The increase in margin was driven by higher revenue. Revenue exceeded analyst estimates by 1.1%. Earnings per share (EPS) also surpassed analyst estimates by 1.9%. Over the next year, revenue is expected to shrink by 1.4% compared to a 7.3% growth forecast for the pharmaceuticals industry in Spain. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has remained flat, which means it is significantly lagging earnings.
分析記事 • Dec 13Faes Farma (BME:FAE) Is Increasing Its Dividend To €0.14The board of Faes Farma, S.A. ( BME:FAE ) has announced that it will be increasing its dividend on the 23rd of December...
Upcoming Dividend • Dec 09Upcoming dividend of €0.14 per shareEligible shareholders must have bought the stock before 16 December 2021. Payment date: 23 December 2021. Payout ratio is a comfortable 72% and this is well supported by cash flows. Trailing yield: 5.1%. Lower than top quartile of Spanish dividend payers (5.3%). Higher than average of industry peers (2.6%).
分析記事 • Nov 29Faes Farma's (BME:FAE) Dividend Will Be Increased To €0.17Faes Farma, S.A. ( BME:FAE ) will increase its dividend on the 23rd of December to €0.17. This takes the dividend yield...
分析記事 • Sep 21Is Faes Farma (BME:FAE) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
分析記事 • Jul 31Faes Farma, S.A. (BME:FAE) Interim Results: Here's What Analysts Are Forecasting For This YearLast week saw the newest half-yearly earnings release from Faes Farma, S.A. ( BME:FAE ), an important milestone in the...
Reported Earnings • Jul 29Second quarter 2021 earnings releasedThe company reported a solid second quarter result with improved earnings and revenues, although profit margins were flat. Second quarter 2021 results: Revenue: €104.1m (up 4.4% from 2Q 2020). Net income: €25.7m (up 3.9% from 2Q 2020). Profit margin: 25% (in line with 2Q 2020). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Reported Earnings • May 04First quarter 2021 earnings releasedThe company reported a decent first quarter result with improved earnings and profit margins, although revenues were weaker. First quarter 2021 results: Revenue: €104.9m (down 14% from 1Q 2020). Net income: €21.5m (up 3.1% from 1Q 2020). Profit margin: 21% (up from 17% in 1Q 2020). The increase in margin was driven by lower expenses.
分析記事 • May 01Is Faes Farma (BME:FAE) Using Too Much Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
分析記事 • Apr 07Estimating The Fair Value Of Faes Farma, S.A. (BME:FAE)Does the April share price for Faes Farma, S.A. ( BME:FAE ) reflect what it's really worth? Today, we will estimate the...
分析記事 • Mar 22Does Faes Farma, S.A. (BME:FAE) Have A Place In Your Dividend Portfolio?Today we'll take a closer look at Faes Farma, S.A. ( BME:FAE ) from a dividend investor's perspective. Owning a strong...
分析記事 • Mar 06Faes Farma's (BME:FAE) Solid Earnings May Rest On Weak FoundationsFaes Farma, S.A.'s ( BME:FAE ) healthy profit numbers didn't contain any surprises for investors. We think this is due...
分析記事 • Feb 22Faes Farma (BME:FAE) Has Compensated Shareholders With A Respectable 61% Return On Their InvestmentWhen we invest, we're generally looking for stocks that outperform the market average. Buying under-rated businesses is...
Is New 90 Day High Low • Jan 18New 90-day high: €3.96The company is up 22% from its price of €3.26 on 20 October 2020. The Spanish market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 3.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €4.14 per share.
分析記事 • Jan 16I Ran A Stock Scan For Earnings Growth And Faes Farma (BME:FAE) Passed With EaseSome have more dollars than sense, they say, so even companies that have no revenue, no profit, and a record of falling...
分析記事 • Dec 08Faes Farma (BME:FAE) Seems To Use Debt Rather SparinglyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Dec 04New 90-day high: €3.90The company is up 19% from its price of €3.27 on 04 September 2020. The Spanish market is up 16% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.
Is New 90 Day High Low • Nov 16New 90-day high: €3.74The company is up 9.0% from its price of €3.44 on 18 August 2020. The Spanish market is up 10.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Pharmaceuticals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.
Is New 90 Day High Low • Oct 29New 90-day low: €3.20The company is down 12% from its price of €3.63 on 30 July 2020. The Spanish market is down 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is down 6.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is €3.50 per share.
